Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 20/20 | 0.60 |
| ▸ | ADRA1A | P35348 | 20/20 | 0.60 |
| ▸ | ADRA1B | P35368 | 19/20 | 0.60 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.60 |
| ▸ | HTR1A | P08908 | 1/20 | 0.60 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.60 |
| ▸ | DRD2 | P14416 | 1/20 | 0.60 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.60 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.60 |
| ▸ | DRD1 | P21728 | 1/20 | 0.60 |
| ▸ | DRD4 | P21917 | 1/20 | 0.60 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.60 |
| ▸ | HTR1D | P28221 | 1/20 | 0.60 |
| ▸ | HTR1B | P28222 | 1/20 | 0.60 |
| ▸ | HTR7 | P34969 | 1/20 | 0.60 |
| ▸ | HRH1 | P35367 | 1/20 | 0.60 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.60 |
| ▸ | DRD3 | P35462 | 1/20 | 0.60 |
| ▸ | HTR2B | P41595 | 1/20 | 0.60 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8469841 | 1.00 | ADRA1D (0.60) | ADRA1DADRA1AADRA1BADRB2HTR1A | |
| SCHEMBL4537580 | 0.91 | ADRA1D (0.52) | ADRA1DADRA1AADRA1BADRB2HTR1A | |
| SCHEMBL524781 | 0.84 | ADRA1D (0.43) | ADRA1DADRA1AADRA1BADRB2HTR1A | |
| Propanol SCHEMBL28660784 | 0.81 | ADRA1D (0.51) | ADRA1DADRA1AADRA1BADRB2HTR1A | |
| SCHEMBL3148298 | 0.77 | ADRA1D (0.65) | ADRA1DADRA1AADRA1BADRB2HTR1A | |
| SCHEMBL14895351 | 0.76 | ADRA1D (0.87) | ADRA1DADRA1AADRA1BADRB2HTR1A | |
| SCHEMBL7266131 | 0.76 | ADRA1D (0.51) | ADRA1DADRA1AADRA1BADRB2HTR1A | |
| Silodosin SCHEMBL31017646 | 0.75 | ADRA1D (1.00) | ADRA1DADRA1AADRA1BADRB2HTR1A | |
| Silodosin SCHEMBL10327491 | 0.75 | ADRA1D (1.00) | ADRA1DADRA1AADRA1BADRB2HTR1A | |
| Silodosin SCHEMBL136973 | 0.75 | ADRA1D (1.00) | ADRA1DADRA1AADRA1BADRB2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012131710-A2 | NOVEL PROCESS FOR THE SYNTHESIS OF INDOLINE DERIVATIVES | PANACEA BIOTEC LTD (IN) | 2012-10-04 | — | — | WO | disclosed |
| WO-2012077138-A1 | METHODS OF CRYSTALLIZING (R) -1- (3 -HYDROXYPROPYL) -5- [2- [2- [2- ( 2, 2, 2 - TRIFLUOROETHOXY) PHENOXY] ETHYLAMINO] PROPYL] INDOLINE-7 -CARBOXAMIDE | PANACEA BIOTEC LIMITED (IN) | 2012-06-14 | — | — | WO | disclosed |
| US-20100076010-A1 | ALPHA 1A-ADRENOCEPTOR ANTAGONISTS | CONCERT PHARMACEUTICALS, INC. | 2010-03-25 | — | — | US | disclosed |
| EP-2125717-A2 | DEUTERATED DERIVATIVES OF SILODOSIN AS ALPHA IA-ADRENORECEPTOR ANTAGONISTS | Concert Pharmaceuticals Inc. (US) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008106125-A2 | DEUTERATED DERIVATIVES OF SILODOSIN AS ALPHA LA-ADRENOCEPTOR ANTAGONISTS | CONCERT PHARMACEUTICALS, INC. (US) | 2008-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076010-A1 | ALPHA 1A-ADRENOCEPTOR ANTAGONISTS | ADRA1D, ADRA1A, ADRB1 | ADRA1D 1/4885ADRA1A 2/4885ADRA1B 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.